Worldwide Emergence of Extensively Drug-resistant Tuberculosis

Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR-TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, N. Sarita, Wright, Abigail, Bai, Gill-Han, Barrera, Lucia, Boulahbal, Fadila, Martín-Casabona, Nuria, Drobniewski, Francis, Gilpin, Chris, Havelková, Marta, Lepe, Rosario, Lumb, Richard, Metchock, Beverly, Portaels, Françoise, Rodrigues, Maria Filomena, Rüsch-Gerdes, Sabine, Van Deun, Armand, Vincent, Veronique, Laserson, Kayla, Wells, Charles, Cegielski, J. Peter
Formato: Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725916/
https://www.ncbi.nlm.nih.gov/pubmed/17552090
http://dx.doi.org/10.3201/eid1303.061400
Descripción
Sumario:Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR-TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000–2004. We defined extensively drug-resistant TB (XDR-TB) as MDR-TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR-TB isolates, 347 (9.9%) met criteria for XDR-TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR-TB are crucial for protection of public health and control of TB.

Ejemplares similares